Headquartered in London and New York with offices worldwide, a private equity firm managing ~$65M in assets under management (AUM). The firm invests in both public and private markets across various industries, with a healthcare-focused team dedicated to private market investments. Their average initial check size ranges from $10M to $30M, with follow-on investments expected. The firm has the ability to led, co-lead, or join a round as a syndicate member.
The firm is interested in opportunities in therapeutics, medical devices, and diagnostics. The firm is agnostic to subsectors and indications and is willing to consider orphan drugs. Within therapeutics, they prefer asset-forward companies but are open to platform companies with lead assets or drugs. Regarding the phase of development, the firm seeks clinical stage companies or companies that are no more than 6-9 months away from the clinical stage.
The firm doesn’t have specific requirements for companies’ management teams. The firm will consider board or observer seats on a case-by-case basis, but this is not a requirement.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment